French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Tag Archive for: SeaBeLife
Biotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.